Skip to main content
See every side of every news story
Published loading...Updated

Year in Review: Alzheimer's Disease

FDA approved the first blood-based tests for Alzheimer's biomarkers and reported multi-year clinical benefits for anti-amyloid drugs lecanemab and donanemab in 2025.

Summary by MedPage Today
(MedPage Today) -- News about Alzheimer's rose to the forefront in 2025, as the FDA approved the first diagnostic blood test and drugmakers reported 3-year outcomes for both anti-amyloid drugs, lecanemab (Leqembi) and donanemab (Kisunla). The...

4 Articles

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 67% of the sources are Center
67% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

South Florida Reporter broke the news in on Friday, November 21, 2025.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal